Friends of Cancer Research initiated a research partnership, inviting HRD assay developers to participate in two blinded analyses. In the first, 11 assay developers reported HRD status for the Cancer ...

A German CDO Supporting Biotech Companies Bringing Biologics from Early Development to ClinicMELBOURNE, Australia, March 10, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” ...

Multiplex assay tech detects multi-biomolecules in single samples on xMAP/CBA, with high sensitivity and consistency ...

Allogene Therapeutics has announced an expanded collaboration with Foresight Diagnostics to develop a minimal residual disease (MRD) assay as a companion diagnostic tool for identifying patients with ...

Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown promising clinical results in the treatment of ovarian cancer. Analysis of biomarker subgroups consistently revealed higher benefits for ...

Next-generation, non-invasive diagnostic platform has potential applications in solid tumor types beyond liver cancerLicensing deal reflects ...

(RTTNews) - Akoya Biosciences, Inc. (AKYA), Thursday announced the launch of a new multiplex immunofluorescence or mIF assay to advance antibody-drug conjugate or ADC development in breast cancer, ...

Assays to measure homologous recombination deficiency (HRD) in ovarian cancer vary widely, underscoring the need for standardization, since inconsistent assay results can influence treatment decisions ...

Please provide your email address to receive an email when new articles are posted on . A 14-gene molecular assay may help predict adjuvant chemotherapy benefit in early NSCLC. Patients assigned ...

Please provide your email address to receive an email when new articles are posted on . The CNSide assay aims to help clinicians with early diagnosis, treatment plans for those with CNS cancers. The ...